FTA will hurt pharmaceutical sector

Korea's first generic makers could lose up to 300 billion won if a U.S.-Korea free trade agreement (FTA) goes through, according to pharmaceutical business sources.

The estimated losses are based on an assumption that if the Korean government sets up a system to suspend the approval process of a generic drug for one year, when the original developer files a complaint about patent violation a...